: Krystal Biotech stock rises after FDA approves treatment for rare skin disease


Krystal Biotech Inc. KRYS, +9.85% shares rose Friday after the biotech drug company received Food and Drug Administration approval of a rare skin disease treatment. Krystal shares rose as much as 8% to an intraday high of $94.61 after the FDA approved the company’s drug Vyjuvek to treat dystrophic epidermolysis bullosa, a rare genetic condition that causes a person’s skin to tear very easily, and lacks any approved treatment. The approval is for patients as young as six months old, the company said.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: As Morgan Stanley looks to replace James Gorman, where are the female bank CEOs?
Next articleInstagram is preparing to launch a text-based rival to Twitter, reports say


Please enter your comment!
Please enter your name here